Express News | Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $36 Price Target

BenzingaFeb 24 06:14 ET

MeiraGTx Hldgs Analyst Ratings

BenzingaFeb 24 06:12 ET · Ratings

MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release

WSJFeb 21 14:41 ET

MeiraGTx Shares Are Trading Higher After the Company Announced the Publication of Results From Its First-in-human Interventional Study to Treat Children With AIPL1-associated Severe Retinal Dystrophy.

BenzingaFeb 21 08:13 ET

MeiraGTx Announces Positive Results From First-in-Human Study of Gene Therapy for AIPL1-Related Retinal Dystrophy in Young Children

Quiver QuantitativeFeb 21 06:40 ET

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of RAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

GlobeNewswireFeb 21 06:30 ET